News - Page 37 - Psychedelic Alpha

Read more about the article Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Post published:June 27, 2023
Post category:Press Release

Read more about the article BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada

BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada

Post published:June 22, 2023
Post category:Press Release

Read more about the article Numinus Announces Agreement with HealingMaps to Drive Strategic Clinic Growth

Numinus Announces Agreement with HealingMaps to Drive Strategic Clinic Growth

Post published:June 22, 2023
Post category:Press Release

Read more about the article Bright Minds Announces Proposed Share Consolidation

Bright Minds Announces Proposed Share Consolidation

Post published:June 22, 2023
Post category:Press Release

Read more about the article Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

Post published:June 21, 2023
Post category:Press Release

Read more about the article Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

Post published:June 20, 2023
Post category:Press Release

Read more about the article PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.

PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.

Post published:June 20, 2023
Post category:Press Release

Read more about the article Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

Post published:June 16, 2023
Post category:Press Release

Read more about the article COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences

COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences

Post published:June 16, 2023
Post category:Press Release

Read more about the article Ibogaine’s Surge in Popularity Could Be a Huge Loss for the Gabonese People Unless We Shift Course

Ibogaine’s Surge in Popularity Could Be a Huge Loss for the Gabonese People Unless We Shift Course

Post published:June 15, 2023
Post category:Opinions

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.